TAG1
- Company typePrivate
- Founded2024
- HeadquartersChesterfield, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
TAG1 firmographics
Firmographics- Name
- TAG1
- Legal name
- TAG1 Inc.
- Website
- https://tag1inc.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TAG1 industry classification
Industry- Product category
- Radiopharmaceuticals / Medical Isotopes
- NAICS
- Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
Keywords
Where TAG1 is headquartered
LocationHeadquarters
- HQ city
- Chesterfield
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TAG1 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Others
Revenue model
- Generator Sales and Isotope Supply: TAG1 supplies its proprietary Lead-212 generators to biotech companies, hospital networks, and research institutions. The company also provides high-purity Lead-212 isotopes directly to enable pre-clinical and clinical research programs.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
TAG1 product offering
Product offeringCore offering
TAG1 designs, manufactures, and supplies its proprietary portable Targeted Alpha Generator 1 (TAG1) system, which produces high-purity Lead-212 (Pb-212) medical radioisotopes from Radium-224 parent isotope. The generator enables nuclear radiopharmacies, hospital networks, and research institutions to generate their own on-site Lead-212 supply for Targeted Alpha Therapies in oncology, and the company also supplies Lead-212 isotopes directly to biotech and pharmaceutical innovators for pre-clinical and clinical programs.
Product overview
TAG1 is a medical isotope company offering a single core product: the proprietary Targeted Alpha Generator 1 (TAG1). This portable generator system produces Lead-212 (Pb-212) isotopes using Radium-224 as the parent isotope. The product enables nuclear radiopharmacies, large hospital networks, and research institutions to generate their own on-site supply of high-purity Lead-212 for targeted alpha therapies in cancer treatment. TAG1 also provides the Lead-212 isotope itself as a service component, along with partnership-based access to their generator technology for pre-clinical and clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Targeted Alpha Generator 1 (TAG1) Proprietary portable generator system designed to produce Lead-212 (Pb-212) isotopes for targeted alpha therapies in cancer treatment. Uses Radium-224 as its parent isotope and enables nuclear radiopharmacies, hospital networks, and research institutions to produce their own supply of Lead-212 isotopes on-site.
- High-Purity Lead-212 (Pb-212) Isotope Supply Direct supply of high-purity Lead-212 isotopes to small biotech and pharmaceutical companies, as well as research institutions, to enable pre-clinical and clinical research programs in targeted alpha therapies for oncology.
Quantifiable outcome
- TAG1 has met all critical to quality parameters to reliably provide pre-clinical quantities of Lead-212
Companies that use TAG1
Customer profileSegments4 records
Ideal customer profiles4 records
TAG1 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TAG1 partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and supporting.
- NRG PALLAS B.V.flagshipTAG1 and NRG PALLAS signed a Letter of Intent (LOI) to jointly advance access to Lead-212 for next-generation cancer therapies across Europe. The partnership combines TAG1's portable Lead-212 generator with NRG PALLAS' Radium-224 production capabilities from their High Flux Reactor in Petten, Netherlands. NRG PALLAS will continue delivering high-purity Ra-224 to TAG1 through 2028, with plans to establish a secure, stable, and open supply platform for Lead-212 throughout Europe. The collaboration supports the Netherlands' Lead4Life initiative for developing Lead-212-based radiopharmaceuticals.
- Dana-Farber Cancer Institute (Molecular Cancer Imaging Facility)coreTAG1 announced a strategic collaboration with the Molecular Cancer Imaging Facility (MCIF) at Dana-Farber Cancer Institute to accelerate development of targeted alpha therapies. TAG1 supplies its proprietary Lead-212 generator technology to enable pre-clinical and clinical research. The collaboration supports both early-stage discovery and translational research, with MCIF researchers gaining access to Lead-212 for testing novel compounds. The partnership aims to democratize Lead-212 supply and create pathways for innovators to advance their compounds.
- NRG PALLAS B.V.flagshipExpanded strategic partnership including a multi-year agreement supporting Radium-224 supply for both US-based and Europe-based Lead-212 generator production. The agreement enables further development and deployment of TAG1's proprietary Lead-212 generator platform in Europe, addressing the growing demand for decentralized isotope access and supporting alpha therapy development in oncology.
- Lead4Life Initiativesupporting
Scale indicators3 records
Recent moves3 records
Expansion highlights3 records
TAG1 competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
TAG1 social profiles
Digital presenceTAG1 financial estimates
Financial estimateRevenue estimate
Valuation estimate
TAG1 leadership team
Management profileNumber of profiles
Profiles1 record
TAG1 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TAG1 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TAG1
What does TAG1 do?
TAG1 designs, manufactures, and supplies its proprietary portable Targeted Alpha Generator 1 (TAG1) system, which produces high-purity Lead-212 (Pb-212) medical radioisotopes from Radium-224 parent isotope. The generator enables nuclear radiopharmacies, hospital networks, and research institutions to generate their own on-site Lead-212 supply for Targeted Alpha Therapies in oncology, and the company also supplies Lead-212 isotopes directly to biotech and pharmaceutical innovators for pre-clinical and clinical programs.
Is TAG1 a public or private company?
TAG1 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TAG1 founded?
TAG1 was founded in 2024. It employs 1 to 10 people.
Where is TAG1 based?
TAG1 is headquartered in Chesterfield, United States, in the North America region.
How does TAG1 make money?
One revenue line is on record: generator Sales and Isotope Supply.
Does TAG1 have an API?
No public API is recorded for TAG1.
What industry is TAG1 in?
TAG1's product category is Radiopharmaceuticals / Medical Isotopes. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 334517 and its SIC code is 3841.